Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations, Neratinib, Nerlynx, Breast, Solid Tumors, Cancer, HER2 mutations, EGFR mutations, Fulvestrant, Trastuzumab, Cervical, Salivary, ERBB2, Exon 18, Metastatic, HR Positive, Lung, Non-Small Cell Lung Cancer (NSCLC), Neoplasms, Neratinib monotherapy, Neratinib and Trastuzumab
Lead Scientist at UCSF
- Michelle Melisko
Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Puma Biotechnology, Inc.
- HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer
- Phase 2 research study
- Study Type
- About 582 people participating
- Last Updated